Oncopeptides joins up with Vector to commercialize blood cancer drug Pepaxto in the Middle East, North Africa
27 Mar 2024
Drug ApprovalLicense out/inAccelerated Approval
About a month after Oncopeptides lost its appeal with the FDA to continue the approval for Pepaxto in multiple myeloma patients, the company announced it’s teaming up with Vector Pharma to commercialize the drug in the Middle East and North Africa.
Vector will distribute the drug, marketed as Pepaxti outside of the US, in the region, which includes Saudi Arabia, Qatar, the United Arab Emirates, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon and Iraq. The companies are splitting the revenues while Vector will take on all of the costs.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.